- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05421195
Clinical Treatment Research of COVID-19-related Olfactory Dysfunction
Clinical Treatment Research of COVID-19-related Olfactory Dysfunction: A Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Hongmeng Yu, Dr
- Phone Number: 862164377134
- Email: hongmengyush@163.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200031
- Recruiting
- Eye & ENT Hospital
-
Contact:
- hongmeng Yu, Dr
- Phone Number: 862164377134
- Email: hongmengyush@fudan.edu.cn
-
Principal Investigator:
- Xicai Sun, Dr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1. Previous diagnosis of COVID-19 infection; 2. Olfactory function was normal in the past, and the olfactory function decreased due to COVID-19 infection, which has occurred more than 2 weeks; 3. Olfactory function test score: TDI ≤ 30; 4.18 ≤ age ≤ 55 years old; 5.Good overall physical condition, without other diseases that may affect the test; 6. No active infection, such as uncontrolled pneumonia; 7. Women with reproductive potential and sexually active men agree to use acceptable and effective contraceptive methods.
Exclusion Criteria:
1. Participants who refuse to sign informed consent; 2. Participants who have other diseases that affect the result, such as trauma, benign and malignant tumors of nasal cavity and paranasal sinuses, intracranial benign and malignant tumors, etc; 3. Participants with uncontrolled concurrent diseases that the researcher believes will interfere with the treatment; 4. Participants who has contraindications to oral corticosteroids, such as serious gastric and duodenal ulcer, diabetes, glaucoma, etc; 5. Participants who have serious neurological or mental diseases, including dementia and seizures; 6.Participants who have oral corticosteroids history within 2 weeks, or who have recently taken a large amount of oral corticosteroids and are not suitable after the evaluation of the researcher; 7. Participants who have used corticosteroids therapy during the treatment of COVID-19 and olfactory function didn't recover; 8. Pregnant or lactating women; 9. persons without personal freedom and independent civil capacity; 10. Participants who have been enrolled in other intervention clinical trials; 11. Participants who with autoimmune diseases; 12. Participants who has any situation that may hinder the compliance of the protocol study or the safety during the study; 13. Other situations that the investigators think are not suitable for the trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Glucocorticoid therapy with olfactory training
olfactory training plus oral Glucocorticoid
|
Oral corticosteroids
repeat and deliberate sniffing of a set of odorants
|
OTHER: Olfactory training
Olfactory training only
|
repeat and deliberate sniffing of a set of odorants
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Olfactory function test result:the sum of the scores of odor threshold (T), odor discrimination (D), and odor identification (I) is TDI.
Time Frame: 3 months
|
Olfactory tests combination of odor threshold (T), odor discrimination (D), and odor identification (I).
The minimum values is zero, the maximum values of odor threshold (T), discrimination (D), and identification (I) is 16, the sum of the scores is TDI, which is between 0 to 48, the higher scores mean a better outcome.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Odor threshold (T), Odor Discrimination (D), Odor Identification (I)
Time Frame: 3 months
|
The scale of odor threshold (T), discrimination (D), and identification (I).The minimum values is zero, the maximum values of odor threshold (T), discrimination (D), and identification (I) is 16, the higher scores mean a better outcome.
|
3 months
|
the Visual Analogue Scale(VAS)of olfactory function
Time Frame: 3 months
|
Participants should value their olfactory function by use the Visual Analogue Scale(VAS), the minimum values is 0, the maximum values is 10, the higher scores mean a better outcome.
|
3 months
|
Questionnaire of Olfactory Disorders
Time Frame: 3 months
|
every patients should answer the Questionnaire of Olfactory Disorders and record the results
|
3 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Xicai Sun, Dr, Eye&ENT Hospital,Fudan University
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- PIOD2022-5V1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Olfactory Dysfunction
-
Mayo ClinicCompleted
-
Eye & ENT Hospital of Fudan UniversityRecruiting
-
M.D. Anderson Cancer CenterElevar TherapeuticsNot yet recruitingMetastatic Olfactory Neuroblastoma | Recurrent Olfactory NeuroblastomaUnited States
-
St. Paul's Hospital, CanadaRecruitingOlfactory DisorderCanada
-
University of Kansas Medical CenterCompleted
-
Centre Hospitalier Universitaire de NiceNot yet recruitingPatients Without an Olfactory Disorder
-
University of WashingtonCompleted
-
Cliniques universitaires Saint-Luc- Université...Active, not recruitingNeurocognitive Disorders | Postoperative Cognitive Dysfunction | Frailty | Perioperative/Postoperative Complications | Olfactory DisorderBelgium
-
Pamela Youde Nethersole Eastern HospitalRecruitingAnosmia | Olfaction Disorders | Hyposmia | Smell Disorders | Smell Loss | Smell Dysfunction | Olfactory ImpairmentHong Kong
Clinical Trials on corticosteroids therapy
-
Peking Union Medical College HospitalRecruitingSevere Checkpoint Inhibitor PneumonitisChina
-
Sohag UniversityRecruitingBronchial AsthmaEgypt
-
Wayne State UniversityChildren's Hospital of Fudan UniversityTerminatedNephrotic Syndrome in ChildrenChina, United States
-
Bispebjerg HospitalUnknown
-
St. Louis UniversityCompleted
-
National Heart, Lung, and Blood Institute (NHLBI)Childhood Asthma Research and Education NetworkCompletedLung Diseases | Asthma
-
Sun Yat-sen UniversityNot yet recruitingArtificial Intelligence | Eye Involvement of Systemic Diseaes | Adverse Drug Effect on Eye
-
Central Hospital, Nancy, FranceUnknownAcute Respiratory Distress Syndrome Secondary to Covid-19France
-
Soroka University Medical CenterUnknownAsthma ExacerbationIsrael
-
National Center for Research Resources (NCRR)Unknown